Fisetin Prolongs Therapy Window of Brain Ischemic Stroke Using Tissue Plasminogen Activator: A Double-Blind Randomized Placebo-Controlled Clinical Trial.
- 2019-01-01
- RCT
- Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 25
- Limin Wang
- Di Cao
- Huijun Wu
- Hongning Jia
- Chaoping Yang
- Lihua Zhang
- PubMed: 31434498
- DOI: 10.1177/1076029619871359
- High evidence
- Clinical
Fisetin dramatically improved the treatment outcomes of the patients with stroke in the delayed OTT strata, as revealed by lower NIHSS scores.
- Effect
- Beneficial
- Effect size
- Large
- Significant
- Yes